-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, NQqKTFeQ7Om28srfbnVHpIPFgErkxJuxWo+f98sN4f30fstOPXoZZNQ0b7W6MqWy XIqMh/dohyDztdArKw4awA== 0000950133-04-003017.txt : 20040804 0000950133-04-003017.hdr.sgml : 20040804 20040804151450 ACCESSION NUMBER: 0000950133-04-003017 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20040804 GROUP MEMBERS: BIOTECH TARGET N.V. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CELL THERAPEUTICS INC CENTRAL INDEX KEY: 0000891293 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911533912 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-48459 FILM NUMBER: 04951476 BUSINESS ADDRESS: STREET 1: 501 ELLIOTT AVE W STREET 2: STE 400 CITY: SEATTLE STATE: WA ZIP: 98119 BUSINESS PHONE: 2062707100 MAIL ADDRESS: STREET 1: 501 ELLIOTT AVE W STREET 2: STE 400 CITY: SEATTLE STATE: WA ZIP: 98119 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: VODERGASSE 3 STREET 2: SWITZERLAND CITY: SCHAFFHAUSEN STATE: V8 ZIP: CH-8300 BUSINESS PHONE: 411724 59 59 MAIL ADDRESS: STREET 1: VODERGASSE 3 STREET 2: SWITZERLAND CITY: SCHAFFHAUSEN STATE: V8 ZIP: CH-8300 SC 13G/A 1 w99783sc13gza.htm AMENDMENT NO. 2 TO SCHEDULE 13G sc13gza
 

     
 
 
 
  OMB APPROVAL
 
 
  OMB Number: 3235-0145
 
 
  Expires: December 31, 2005
 
 
  Estimated average burden hours per response. . . 11
 
 

United States
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

Cell Therapeutics Inc.


(Name of Issuer)

Common Stock, no par value


(Title of Class of Securities)

150-934-10-7


(CUSIP Number)

July 28, 2004


(Date of Event Which Requires Filing This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[  ]      Rule 13d-1(b)

[X]      Rule 13d-1(c)

[  ]      Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed “ for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 6


 

                                         
CUSIP No.   150-934-10-7                            
         
 
                           
 
                                       
   
1.
    Names of Reporting Persons   BB Biotech AG
     
       
 
 
   
                                 
     
    I.R.S. Identification Nos. of above persons (entities only):     N/A  
 
   
                           
 
 
   
                                 
   
2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
 
   
                                 
   
    (a)   [X]                            
 
   
                                 
   
    (b)   [  ]                            
 
   
                                 
 
3.
    SEC Use Only                            

 
 
                                       
    4.     Citizenship or Place of Organization               Switzerland
                           
 
 
    Number of Shares Beneficially     5.     Sole Voting Power     0  
  Owned by Each Reporting                      
 
  Person with:                            
          6.     Shared Voting Power     2,602,000  
                                 
 
 
                                       
                  7.     Sole Dispositive Power     0  
                                 
 
 
                                       
                  8.     Shared Dispositive Power   2,602,000
                                 
 
 
                                       
    9.     Aggregate Amount Beneficially Owned
by Each Reporting Person
  2,602,000
                             
 
 
                                       
    10.     Check if the Aggregate Amount in Row (9) Excludes Certain Shares       [  ]
 
                                       
    11.     Percent of Class Represented by amount in Row (9)     4.4 %
                                 
 
 
                                       
    12.     Type of Reporting Person (See Instructions)   HC,CO
                             
 

Page 2 of 6


 

                                         
CUSIP No.      150-934-10-7                            
         
 
                           
 
                                       
   
1.
    Names of Reporting Persons   Biotech Target N.V.
     
       
 
 
   
                                 
     
    I.R.S. Identification Nos. of above persons (entities only):     N/A  
 
   
                           
 
 
   
                                 
   
2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
 
   
                                 
   
    (a)   [X]                            
 
   
                                 
   
    (b)   [  ]                            
 
   
                                 
 
3.
    SEC Use Only                            

 
 
                                       
    4.     Citizenship or Place of Organization               Netherlands Antilles
                           
 
 
    Number of Shares Beneficially     5.     Sole Voting Power     0  
  Owned by Each Reporting                      
 
  Person with:                            
          6.     Shared Voting Power     2,602,000  
                                 
 
                                       
                  7.     Sole Dispositive Power     0  
                                 
 
 
                                       
                  8.     Shared Dispositive Power   2,602,000
                                 
 
 
                                       
    9.     Aggregate Amount Beneficially Owned
by Each Reporting Person
  2,602,000
                             
 
 
                                       
    10.     Check if the Aggregate Amount in Row (9) Excludes Certain Shares       [  ]
 
                                       
    11.     Percent of Class Represented by amount in Row (9)     4.4 %
                                 
 
 
                                       
    12.     Type of Reporting Person (See Instructions)   CO
                             
 

Page 3 of 6


 

Item 4.  Ownership

     Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

                         
    (a)   Amount beneficially owned:   2,602,000    
               
 
   
    (b)   Percent of class:   4.4%    
               
 
   
    (c)   Number of shares as to which the person has:
 
        (i)   Sole power to vote or to direct the vote   0
                   
 
        (ii)   Shared power to vote or to direct the vote   2,602,000
                   
 
        (iii)   Sole power to dispose or to direct the disposition of   0
                   
 
        (iv)   Shared power to dispose or to direct the disposition of   2,602,000
                   
 

Item 5.  Ownership of Five Percent or Less of a Class

     If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

Page 4 of 6


 

Item 10.  Certification

     By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURES

     After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

               
BB BIOTECH AG        
    /s/ ROLAND MAIER       /s/ ADRIAN BRUENGGER

 
 
 
By:
Its:
Date:
  Roland Maier
Authorized Signatory
August 3, 2004
  By:
Its:
Date:
  Adrian Bruengger
Authorized Signatory
August 3, 2004
BIOTECH TARGET N.V.        
    /s/ ROLAND MAIER       /s/ ADRIAN BRUENGGER

 
 
 
By:
Its:
Date:
  Roland Maier
Authorized Signatory
August 3, 2004
  By:
Its:
Date:
  Adrian Bruengger
Authorized Signatory
August 3, 2004

Page 5 of 6


 

EXHIBIT INDEX

     
Exhibit 1:
  Agreement by and between BB Biotech AG and Biotech Target N.V. with respect to the filing of this disclosure statement.*

 

 

 

 

 

 

 


*   Previously filed.

Page 6 of 6

-----END PRIVACY-ENHANCED MESSAGE-----